Genovyn logo

Finding a cure requires leadership that can look beyond the horizon.

Three scientists in white lab coats stand smiling in a modern laboratory, with lab equipment and another person working in the background.

Innovation for the Most Urgent Medical Needs

Genovyn’s discovery and development model leads to improved success rates and significantly reduces development time and cost to market. Genovyn’s companies are therapeutically focused, tactically nimble, and benefit from operational efficiencies provided centrally by Genovyn.  Our subsidiaries or “Vyns” and their leadership teams are Therapeutically aligned experts focused on the development mission.

We are rethinking traditional drug development by pioneering therapies designed to move beyond conventional pathways, unlocking new possibilities where options have long been limited. Guided by innovation, collaboration, and an unwavering commitment to patients, Genovyn is charting a bold course toward a future where devastating diseases can be met with real solutions.

An older woman wearing sunglasses and floral clothing smiles while taking a selfie outdoors, with sunlight and a blurred background suggesting she is near water.

Our Business Model

Genovyn’s integrated discovery and development model enhances program success rates while reducing both time and cost to market. Our portfolio companies—known as “Vyns”—are therapeutically focused and operationally agile, leveraging the centralized infrastructure, resources, and expertise of the Genovyn platform.

Each Vyn is led by seasoned domain experts aligned around a clear therapeutic mission, combining scientific rigor with strategic execution. This structure enables Genovyn to scale innovation efficiently across diverse therapeutic areas while maintaining focus, speed, and capital discipline.

A flowchart for Genovyn Corporate Service shows stages from Discovery & Preclinical to Clinical and Commercialization, featuring products: tripsovyn, panevyn, immunovyn, and datavyn for various diseases and data analytics.

Unmatched Leadership

Genovyn is led by a dynamic and driven leadership team dedicated to transforming cutting-edge science into life-changing therapies. With deep expertise spanning drug discovery, clinical development, and regulatory strategy, we are focused on addressing critical unmet needs in oncology and immunology. Our mission is to advance innovative drug candidates from concept to commercialization, accelerating the path from scientific discovery to meaningful patient impact.

A mature man with short white hair, identified as Jeff Bagshaw, wears a light gray suit jacket and light blue shirt, posing while seated in a modern, blurred office setting. He looks directly at the camera with a neutral expression.
Jeff Bagshaw

Chairman & Chief Executive Officer | Genovyn

Jeff is a global life sciences executive with more than 30 years of experience spanning biotechnology, clinical research, and pharmaceutical commercialization. As Chairman and CEO of Genovyn, he leads the company’s mission to advance innovative therapeutic platforms through scientific excellence, strategic partnerships, and operational precision.

With a deep expertise in clinical development and global commercialization, Jeff has guided organizations through every phase of growth—from early clinical strategy and regulatory execution to global market expansion.

A middle-aged man with short light hair, identified as Jeff Reiniche, smiles at the camera. He is wearing a checked shirt indoors, with part of another person's face partially visible on the right side.
Jeff Reiniche

Chief Financial & Business Officer | Genovyn

Jeff Reiniche is an accomplished finance and strategy executive with extensive experience in biotechnology, clinical research, and corporate growth. As Chief Financial and Business Officer of Genovyn, he oversees financial strategy, capital development, and M&A initiatives that align innovation with sustainable enterprise value. Jeff previously served as CFO at Inclinix and held senior leadership roles at Click Commerce and PricewaterhouseCoopers, guiding large-scale transactions and integrations. Over his career, he has led investments and acquisitions ranging from $10 million to $2 billion, recognized for combining financial rigor with strategic insight to drive growth across the life sciences sector.

Our Advisory Board

Claudio Faria, a man with short gray hair wearing a light gray suit jacket and white shirt, smiles at the camera against a dark gray background.
Claudio Faria, PharmD

Chairman and CEO at Ignite BioMedical

Smiling older man with grey hair and mustache wearing a grey suit, patterned tie, and a pink ribbon pin on his lapel, posed against a dark background. This is Stefan Glück.
Stefan Glück, MD

Practicing Oncologist, Speaker, and former Head of Oncology for Regeneron

Sare Largay, a woman with long dark hair, wears a navy blazer over a white top and stands smiling with her arms crossed against a plain light gray background.
Sare Largay, Esq.

Chief Operating Officer for North America at Miltenyi Biomedicine

Chris Legg, a man with short, dark hair wearing a navy suit jacket and light blue shirt, stands in front of a plain light gray background, smiling slightly at the camera.
Chris Legg

Chief Operating Officer at CureLab

Dr. David Levine, a smiling man in a suit and tie, stands indoors in front of white shelves adorned with decorative vases and a framed photo.
Dr. David Levine, DC

Rare Disease, Endocrinology & Metabolic Executive at Pfizer

About the “-vyn”

The “-vyn” suffix unites each of our portfolio companies under a shared vision: to develop and deliver transformative therapies. While each “vyn” operates with focus and autonomy, all are built on a common platform—aligned in science, strategy, and purpose. Together, they form a cohesive ecosystem aimed at improving lives through innovation.

A blank, black-outlined speech bubble with a pointed tail on the lower left, set against a plain white background.

I am a heading